Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection

Table 2 Background characteristics of the patients according to the treatment group before the propensity score matching

	EPZ group	OPZ group	P value
Number	71	172
Age (yr)	75.3 ± 7.1	72.9 ± 8.5	0.0361
Gender (M/F)	52/19	124/48	0.86
Antiplatelet/anticoagulant drugs (-/+)	50/21	136/36	0.15
Hypertension (-/+)	40/31	103/69	0.61
Diabetes Mellitus (-/+)	Sep-62	151/21	0.92
H. pylori infection (-/+)	29/42	55/117	0.19
Location (U/M/L)	10/34/27	20/77/75	0.7
Depth (m/sm)	57/14	161/11	0.0019
Ulcer (-/+)	71/0	167/5	0.15
Diameter of the lesion (mm)	42.2 ± 17.2	40.14 ± 14.1	0.31
Duration of the operation (min)	115.9 ± 87.3	106.4 ± 61.1	0.34
Macroscopic type of the lesion (elevated or flat/combined/depressed)	46/16/9	102/18/52	0.003
Pathological findings (Adenoma/Differentiated ca/Undifferentiated ca)	26/42/3	62/105/5	0.86
Lymphatic/venous invasion (-/+)	Jan-70	168/4	0.65
Anastomosis (-/+)	Mar-68	163/9	0.74
Operator type (expert/beginner)	31/40	112/60	0.002
Bleeding during ESD (good/poor control)	55/16	134/38	0.94
Hemorrhage after ESD (-/+)	149/23	Oct-61	0.88
Clinically significant bleeding (-/+)	165/7	Mar-68	0.96

P value calculated by the χ² test (Fisher’s exact test or Pearson’s test). EPZ: Esomeprazole; OPZ: Omeprazole; ESD: Endoscopic submucosal dissection.